BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia

BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia

Abstract Background BCL2 protein inhibitor venetoclax (ABT-199) has been authorized by Food and Drug Administration for relapsed/refractory chronic lymphoid leukemia with 17p deletion. Although venetoclax/ABT-199 also caused cell death in acute myeloid leukemia (AML), whether it could be applied to...

Full description

Bibliographic Details
Main Authors: Jing-dong Zhou, Ting-juan Zhang, Zi-jun Xu, Yu Gu, Ji-chun Ma, Xi-xi Li, Hong Guo, Xiang-mei Wen, Wei Zhang, Lei Yang, Xing-hui Liu, Jiang Lin, Jun Qian
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Diagnostic Pathology
Subjects:
BCL2
Expression
HSCT
ABT-199/venetoclax
AML
Online Access:http://link.springer.com/article/10.1186/s13000-019-0841-1

Internet

http://link.springer.com/article/10.1186/s13000-019-0841-1

Similar Items